Advertisement
UK markets close in 8 hours 12 minutes
  • FTSE 100

    8,077.15
    +32.34 (+0.40%)
     
  • FTSE 250

    19,807.25
    +7.53 (+0.04%)
     
  • AIM

    755.94
    +1.07 (+0.14%)
     
  • GBP/EUR

    1.1633
    +0.0005 (+0.04%)
     
  • GBP/USD

    1.2435
    -0.0018 (-0.14%)
     
  • Bitcoin GBP

    53,737.57
    +389.92 (+0.73%)
     
  • CMC Crypto 200

    1,417.68
    -6.42 (-0.45%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    83.44
    +0.08 (+0.10%)
     
  • GOLD FUTURES

    2,336.70
    -5.40 (-0.23%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,208.53
    +379.60 (+2.26%)
     
  • DAX

    18,180.51
    +42.86 (+0.24%)
     
  • CAC 40

    8,105.78
    0.00 (0.00%)
     

Worldwide Active Pharmaceutical Ingredients (API) Industry to 2026 - Key Players Include Pfizer, Novartis and Sanofi Among Others

Dublin, June 02, 2021 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients (API) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global active pharmaceutical ingredients (API) market reached a value of US$ 200.6 Billion in 2020. Active pharmaceutical ingredient (API), is the term that is used to refer to the biologically active component of a drug (e.g. tablet, capsule). A drug is usually composed of several components. The API represents the primary ingredient. Other ingredients are commonly known as "excipients. Sometimes a drug can contain several APIs and its effect on a patient depends on the dosage prescribed and can vary from person to person. In combination therapies, two or more than two active ingredients are used to treat different symptoms in different ways. Stringent quality control is a mandate when it comes to the manufacturing of drugs as the API represents the main component considered while making the prescription.

Pharmaceutical manufacturing occurs in two general steps. In the first step, manufacturers convert raw materials into APIs. The second step involves creating the final formulation by mixing APIs and excipients into tablets, capsules, solutions, etc. and finally packaging the drug for the end users. Manufacturers either sell APIs in the open market (also known as the merchant market) or use them as inputs to make their final formulations. The global API market is extremely competitive with a number of large and small manufacturers. Firms that engage in API manufacturing generally specialize and target their manufacturing based on a combination of the firms in-house skills and market opportunities. Catalyzed by lower costs, API manufacturing has gradually been shifting from the historical leaders in Western countries to manufacturers based in India and China.

The global demand of APIs is currently exhibiting strong growth. One of the major drivers of this market is the rising number of blockbuster patent expiries creating a significant opportunity for generic APIs. Moreover, there has been a strong demand for APIs for biologicals. The global market for biologicals is currently exhibiting strong growth catalyzed by their high potency and ability to treat diseases beyond the scope of small molecule drugs. This is creating a strong demand for APIs for branded biological drugs and their biosimilar versions. Other factors catalyzing the global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the publisher expects the global active pharmaceutical ingredients (API) market to exhibit moderate growth during the forecast period (2021-2026).

Market Segmentation:

Break up by Drug Type:

  • Innovative Active Pharmaceutical Ingredients (API)

  • Generic Active Pharmaceutical Ingredients (API)

Based on the drug type, the market has been segmented as innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients.

Break up by Manufacturer:

  • Captive Manufacturers

  • Merchant API Manufacturers

  • Innovative Merchant API Manufacturers

  • Generic Merchant API Manufacturers

ADVERTISEMENT

Based on the type of manufacturer, the market has been segmented as captive manufacturers and merchant API manufacturers.

Break up by Synthesis

  • Synthetic Active Pharmaceutical Ingredients (API)

Market Breakup by Type

  • Innovative Synthetic APIs

  • Generic Synthetic APIs

  • Biotech Active Pharmaceutical Ingredients (API)

Market Breakup by Type

  • Innovative Biotech APIs

  • Biosimilars

Market Breakup By Product

  • Monoclonal Antibodies

  • Vaccines

  • Cytokines

  • Fusion Proteins

  • Therapeutic Enzymes

  • Blood Factors

Market Breakup By Expression System

  • Mammalian Expression Systems

  • Microbial Expression Systems

  • Yeast Expression Systems

  • Transgenic Animal Systems

  • Others

Based on the type of synthesis, the market has been segmented as synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients.

Break up by Therapeutic Application:

  • Oncology

  • Cardiovascular and Respiratory

  • Diabetes

  • Central Nervous System Disorders

  • Neurological Disorders

  • Others

Based on the therapeutic application, the market has been segmented as oncology, cardiovascular & respiratory, diabetes, central nervous system disorders, neurological disorders and others.

Break up by Region:

  • North America

  • United States

  • Canada

  • Europe

  • Germany

  • France

  • United Kingdom

  • Italy

  • Spain

  • Russia

  • Others

  • Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Others

  • Latin America

  • Middle East and Africa

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape:

The competitive landscape of the market has also been examined with some of the (active pharmaceutical ingredients companies) key players being Pfizer, Inc., Novartis International AG, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., ELI Lilly and Company, GlaxoSmithKline, Merck & Co., Inc. and Abbvie Inc.

Key Questions Answered in This Report:

  • How has the global active pharmaceutical ingredients (API) market performed so far and how will it perform in the coming years?

  • What has been the impact of COVID-19 on the global active pharmaceutical ingredients (API) industry?

  • What are the key regional markets in the global active pharmaceutical ingredients (API) industry?

  • What is the breakup of the global active pharmaceutical ingredients (API) market on the basis of drug type?

  • What is the breakup of the global active pharmaceutical ingredients (API) market on the basis of type of manufacturer?

  • What is the breakup of the global active pharmaceutical ingredients (API) market on the basis of synthesis?

  • What is the breakup of the global active pharmaceutical ingredients (API) market on the basis of therapeutic application?

  • What are the various stages in the value chain of the global active pharmaceutical ingredients (API) market?

  • What are the key driving factors and challenges in the global active pharmaceutical ingredients (API) market?

  • What is the structure of the global active pharmaceutical ingredients (API) market and who are the key players?

  • What is the degree of competition in the global active pharmaceutical ingredients (API) market?

  • How are active pharmaceutical ingredients (API) manufactured?

Key Topics Covered:

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Active Pharmaceutical Ingredients (API) Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Drug Type
5.5 Market Breakup by Type of Manufacturer
5.6 Market Breakup by Type of Synthesis
5.7 Market Breakup by Therapeutic Application
5.8 Market Breakup by Region
5.9 Market Forecast
5.10 SWOT Analysis
5.10.1 Overview
5.10.2 Strengths
5.10.3 Weaknesses
5.10.4 Opportunities
5.10.5 Threats
5.11 Value Chain Analysis
5.12 Porters Five Forces Analysis
5.12.1 Overview
5.12.2 Bargaining Power of Buyers
5.12.3 Bargaining Power of Suppliers
5.12.4 Degree of Competition
5.12.5 Threat of New Entrants
5.12.6 Threat of Substitutes
5.13 Price Analysis
5.13.1 Price Indicators
5.13.2 Price Structure

6 Market Breakup by Drug Type
6.1 Innovative Active Pharmaceutical Ingredients (API)
6.2 Generic Active Pharmaceutical Ingredients (API)

7 Market Breakup by Type of Manufacturer
7.1 Captive Manufacturers
7.2 Merchant API Manufacturers
7.2.1 Innovative Merchant API Manufacturers
7.2.2 Generic Merchant API Manufacturers

8 Market Breakup by Type of Synthesis
8.1 Synthetic Active Pharmaceutical Ingredients (API)
8.1.1 Market Breakup by Type
8.1.1.1 Innovative Synthetic APIs
8.1.1.2 Generic Synthetic APIs
8.2 Biotech Active Pharmaceutical Ingredients (API)
8.2.1 Market Breakup by Type
8.2.1.1 Innovative Biotech APIs
8.2.1.2 Biosimilars
8.2.2 Market Breakup by Product
8.2.2.1 Monoclonal Antibodies
8.2.2.2 Vaccines
8.2.2.3 Cytokines
8.2.2.4 Fusion Proteins
8.2.2.5 Therapeutic Enzymes
8.2.2.6 Blood Factors
8.2.3 Market Breakup by Expression System
8.2.3.1 Mammalian Expression Systems
8.2.3.2 Microbial Expression Systems
8.2.3.3 Yeast Expression Systems
8.2.3.4 Transgenic Animal Systems
8.2.3.5 Others

9 Market Breakup by Therapeutic Application
9.1 Oncology
9.2 Cardiovascular and Respiratory
9.3 Diabetes
9.4 Central Nervous System Disorders
9.5 Neurological Disorders
9.6 Others

10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 United Kingdom
10.2.4 Italy
10.2.5 Spain
10.2.6 Russia
10.2.7 Others
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Indonesia
10.3.7 Others
10.4 Latin America
10.5 Middle East and Africa

11 API Manufacturing Process
11.1 Product Overview
11.2 Raw Material Requirements
11.3 Manufacturing Process
11.4 Key Success and Risk Factors

12 Competitive Landscape
12.1 Market Structure
12.2 Key Players
12.3 Profiles of Key Players
12.3.1 Pfizer, Inc.
12.3.2 Novartis International AG
12.3.3 Sanofi
12.3.4 Boehringer Ingelheim
12.3.5 Bristol-Myers Squibb
12.3.6 Teva Pharmaceutical Industries Ltd.
12.3.7 ELI Lilly and Company
12.3.8 GlaxoSmithKline
12.3.9 Merck & Co., Inc.
12.3.10 Abbvie Inc

For more information about this report visit https://www.researchandmarkets.com/r/u58hay

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900